Application effect of irbesartan combined with spironolactone on chronic heart failure and its effect on cardiac function
10.3969/j.issn.1005-1678.2017.07.143
- VernacularTitle:厄贝沙坦联合螺内酯在慢性心衰中的应用效果及对患者心功能的影响
- Author:
Yingqing CHEN
- Keywords:
irbesartan;
spironolactone;
chronic heart failure
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(7):346-348
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of irbesartan combined with spironolactone on chronic heart failure and its effect on cardiac function.Methods 60 cases of patients with chronic heart failure treated in our hospital from February 2015 to February 2016 were randomly divided into the control group and the observation group, 30 cases in each group.The control group was treated with conventional therapy, the observation group was treated with irbesartan and spironolactone.The clinical efficacy, cardiac function indexes,blood pressure,heart rate,serum BNP and hs-CRP levels were observed in the 2 groups.Results After treatment, the total effective rate of the observation group was 86.67%(28/30)compared with the control group 63.33%(19/30), and the difference was statistically significant(P<0.05);cardiac function was improved in the two groups compared with before treatment, but the improvement in the observation group was more obvious[LVDd(52.33±4.92)mm vs(59.46±5.57)mm, LVSd(40.24±4.13)mm vs(46.95±4.87)mm, LVEF(48.62±7.13)% vs(42.41±6.65)%], the difference was statistically significant(P<0.05);Blood pressure and heart rate were decreased in the two groups before treatment, but the observation group decreased more significantly[diastolic pressure(75.36±3.54)mmHg vs(85.47±4.09)mmHg, systolic pressure(130.65±8.74)mmHg vs(139.22±9.35)mmHg, heart rate(76.72±10.56)times/min vs(82.59±11.34)times/min], the difference was statistically significant(P<0.05);the levels of BNP and hs-CRP in the two groups were lower than before treatment, but the observation group decreased more significantly[BNP(1.71±0.34)ng/mL vs(2.48±0.57)ng/mL,hs-CRP(6.26±1.03)μg/mL vs(8.79±1.12)μg/mL,the difference was statistically significant(P<0.05).Conclusion Irbesartan combine spironolactone treat with chronic heart failure have reliable curative effect, and it can effectively improve the patient's heart function, delay the development of the disease.
